

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Nijhawan Pardeep</u> (Last) (First) (Middle) C/O EDESA BIOTECH INC. 100 SPY COURT (Street) MARKHAM A6 L3R 5H6 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Edesa Biotech, Inc. [EDSA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Executive Officer
	3. Date of Earliest Transaction (Month/Day/Year) 10/30/2024	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A-1 Convertible Preferred Shares	\$3.445	10/30/2024		A		150		10/30/2024	(1)	Common Stock	435,414 ⁽²⁾	(3)	150	I	Held by Pardeep Nijhawan Medicine Professional Corporation ⁽⁴⁾
Warrants (right to buy)	\$3.445	10/30/2024		A		326,560		10/30/2024	10/30/2029	Common Stock	326,560	(3)	326,560	I	Held by Pardeep Nijhawan Medicine Professional Corporation ⁽⁴⁾

Explanation of Responses:

- The Preferred Shares are perpetual and therefore have no expiration date.
- Each Preferred Share is convertible at any time, at the option of the holder, into a number of common shares determined by dividing the stated value of the Preferred Share (\$10,000 per share), plus any accrued and unpaid dividends, by the conversion price at the time of conversion. Until the three-year anniversary of the day of issuance, holders of Preferred Shares are entitled to an annual return equal to 10% of the stated value per Preferred Share payable by the issuance of common shares at the conversion price upon a buy-back by the Issuer, liquidation or on conversion at the conversion price (calculated daily).
- On October 30, 2024, the Reporting Person purchased in a private placement, (i) 150 shares of the Issuer's newly designated Series A-1 Convertible Preferred Shares (the "Preferred Shares"), stated value \$10,000 per share and (ii) warrants (the "Warrants") to purchase up to an aggregate of 326,560 common shares. The Preferred Shares are immediately convertible, and the Warrants are immediately exercisable, at \$3.445 per share, in each case, to the extent that after giving effect to such conversion and/or exercise the Reporting Person and his affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding common shares of the Issuer. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the common shares underlying the Preferred Share at a combined purchase price of \$10,272.13.
- Pardeep Medicine Professional Corporation is wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

/s/ Stephen Lemieux, Attorney-in-Fact for Pardeep Nijhawan 11/01/2024
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.